ReviewJournal of cancer research and clinical oncology2021
Gut microbiota-derived metabolites in CRC progression and causation.
Review in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 93 citations in OpenAlex.
- Gastrointestinal Microbiome Dysbiosis in Cancer Development: Mechanisms and Biomarker Potential.MicrobiologyOpen · 2026Review
- Gut microbiota modulation of gastrointestinal cancers: from dysbiosis signatures to therapeutic interventions.Acta pharmacologica Sinica · 2026Review
- Gut microbiome derived folate metabolite suppresses colorectal cancer progression.bioRxiv : the preprint server for biology · 2026Article
- Gut Microbiota in Colorectal Cancer: Mechanisms of Carcinogenesis, Biomarkers, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- The Causal Role of Bile Acids in Cancers of the Digestive System.Biomedicines · 2026Review
- Gut metabolites: key factors in the cross-talk between the gut microbiota and tumor immunotherapy.Frontiers in immunology · 2026Review
- Crosstalk between mFrontiers in immunology · 2026Review
- Gut microbiota-derived metabolites in gastrointestinal cancer: immunomodulatory mechanisms via the tryptophan-AhR axis and translational perspectives.Frontiers in immunology · 2026Review
- Progress on the regulation of colorectal cancer and cardio-oncology by the gut microbiota and nutrients.Frontiers in immunology · 2026Review
- Microbial metabolite trimethylamine-N-oxide facilitates colorectal inflammation-cancer transformation by blocking lysosomal degradation of Wnt signaling.Gut microbes · 2025Article
- Potential Impact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer.Biomedicines · 2025Article
- The antimicrobial metabolite nisin Z reduces intestinal tumorigenesis and modulates the cecal microbiome in ApcMicrobiology spectrum · 2025Article
- Gut Microbiome Alterations in Colorectal Cancer: Mechanisms, Therapeutic Strategies, and Precision Oncology Perspectives.Cancers · 2025Review
- The functional landscape of the appendix microbiome under conditions of health and disease.Gut pathogens · 2025Review
- Identification and impact of microbiota-derived metabolites in ascites of ovarian and gastrointestinal cancer.Cancer & metabolism · 2025Article
- Gut microbiome in colorectal cancer: metagenomics from bench to bedside.JNCI cancer spectrum · 2025Review
- Gut microbiota plays a key role in the development of colorectal cancer.World journal of gastroenterology · 2025Article
- Oral intake of Hibiscus sabdariffa L. increased c-Myc and caspase-3 gene expression and altered microbial population in colon of BALB/c mice induced to preneoplastic lesions.European journal of nutrition · 2025Article
- Review
- Bacteroides ovatus-derived N-methylserotonin inhibit colorectal cancer via the HTR1D-mediated cAMP-PKA-NF-κB signaling axis.Frontiers in immunology · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBased on recent research reports, dysbiosis and improper concentrations of microbial metabolites in the gut may result into the carcinogenesis of colorectal cancer. Recent advancement also highlights the involvement of bacteria and their secreted metabolites in the cancer causation. Gut microbial metabolites are functional output of the host-microbiota interactions and produced by anaerobic fermentation of food components in the diet. They contribute to influence variety of biological mechanisms including inflammation, cell signaling, cell-cycle disruption which are majorly disrupted in carcinogenic activities. PURPOSE: In this review, we intend to discuss recent updates and possible molecular mechanisms to provide the role of bacterial metabolites, gut bacteria and diet in the colorectal carcinogenesis. Recent evidences have proposed the role of bacteria, such as Fusobacterium nucleaturm, Streptococcus bovis, Helicobacter pylori, Bacteroides fragilis and Clostridium septicum, in the carcinogenesis of CRC. Metagenomic study confirmed that these bacteria are in increased abundance in CRC patient as compared to healthy individuals and can cause inflammation and DNA damage which can lead to development of cancer. These bacteria produce metabolites, such as secondary bile salts from primary bile salts, hydrogen sulfide, trimethylamine-N-oxide (TMAO), which are likely to promote inflammation and subsequently cancer development.
conclusionRecent studies suggest that gut microbiota-derived metabolites have a role in CRC progression and causation and hence, could be implicated in CRC diagnosis, prognosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.